Epitalon vs Elamipretide
Elamipretide has multiple modern controlled human trials and a narrow disease-specific regulatory pathway; Epitalon longevity claims rely on older regional and preclinical/cell evidence.
| Attribute | Epitalon | Elamipretide |
|---|---|---|
| Human evidence | Older regional human evidence includes a 162-patient retinitis-pigmentosa study using a highly specific parabulbar route. Modern 2025 telomere findings are in cultured human cells, not a longevity trial. No large independent human lifespan trial was identified. | Elamipretide has multiple human trials. In primary mitochondrial myopathy, small early studies showed signals but the 218-person Phase III MMPOWER-3 trial missed both co-primary endpoints. Barth syndrome follows a separate rare-disease evidence and regulatory pathway and should not be generalized to wellness use. |
| Research focus | Ageing biology, telomere research, retinal research | Mitochondrial disease; Barth syndrome; broader mitochondrial research |
| Regulatory status | Not FDA-approved; compounded-use safety information is insufficient. | Forzinity (elamipretide) received FDA accelerated approval for Barth syndrome patients ≥30 kg; this does not make generic SS-31 vials approved. |
| Route / formulation | Do not confuse Epitalon (tetrapeptide) with Epithalamin (pineal extract) when citing older literature. | Generic SS31 research products are not equivalent to Forzinity and may differ in quality/formulation. |
Why these are compared
These compounds appear in the longevity / mitochondrial interest evidence landscape, but they are not interchangeable. Epitalon is tetrapeptide studied in ageing biology, telomere research, retinal research; Elamipretide is mitochondria-targeted tetrapeptide studied in mitochondrial disease; barth syndrome; broader mitochondrial research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Epitalon: Older indication-specific human evidence + modern in-vitro biology; longevity efficacy unproven.
Elamipretide: PMM Phase III negative; FDA accelerated approval for narrow Barth syndrome indication.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
Not therapeutically equivalent. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.